|Bid||4,700.00 x 51000|
|Ask||4,800.00 x 53800|
|Day's Range||4,731.00 - 4,788.00|
|52 Week Range||2,707.19 - 5,377.00|
|PE Ratio (TTM)||147.03|
|Dividend & Yield||0.26 (0.42%)|
|1y Target Est||N/A|
Shares of Xenetic Biosciences sank on Monday after the Lexington biotech announced a significant setback in its collaboration with Shire plc on a hemophilia drug. Xenetic (XBIO), which has seven employees, announced disappointing results from a Phase 1/2 study of Shire’s SHP656 hemophilia A treatment using Xenetic’s PolyXen technology, which is designed to extend the half-life of drugs. While the technology did extend the half-life of SHP656, and there were no major side effects, Xenetic said the trial had missed its goal of enabling once-weekly dosing.
Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.